Universiteit Leiden

nl en

Leiden Early Drug Discovery & Development

LED3 Chemical Biology Talks

The LED3 Network, consisting of researchers from the Leiden Institute of Chemistry (LIC), the Institute of Biology Leiden (IBL) and the Leiden Academic Centre for Drug Research (LACDR), is very excited to organise the “LED3 Chemical Biology Talks”. This lecture series brings excellent researchers in the field of Chemical Biology to our university, and exposes our students to top science conducted in this area.

Furthermore, it strengthens the network and the active exchange of researchers interested in Chemical Biology across our three member institutes and, in this way, fosters interdisciplinary research in the field of Chemical Biology at Leiden University.

The lecture series exemplifies the focus of Leiden University on understanding biological processes at the molecular level to strengthen the knowledge base of human health and disease. The series is open for all, but especially aimed at researchers with an interest in Chemical Biology and its application for drug discovery.

The LED3 Chemical Biology Talks will be held approximately once a month. The format is an approximately 45 min lecture followed by a Q&A session and an informal "meet-and-greet" outside the lecture hall, in which interested researchers can get in direct contact with the speakers.

Agenda

Thu 26 January:
Prof. Christian Heinis

EPFL
Towards the development of orally available peptide therapeutics




 

Tom Grossmann (VU Amsterdam)
Akane Kawamura (Newcastle University/University of Oxford)
Carolyn Bertozzi (Stanford University)
Craig Crews (Yale University)
Matt Bogyo (Stanford University)
Andreas Marx (Universität Konstanz)
Benjamin Cravatt (The Scripps Research Institute)
Tom Wennekes (Universiteit Utrecht)
Benjamin G. Davis (University of Oxford)
Chris Schofield (Oxford University, Chemistry Research Laboratory)
Roderich Süssmuth (Technische Universität Berlin)
John Sutherland (University of Cambridge)
Joseph Fox (University of Delaware)
Peter Cresswell (Yale University)
Derek Lowe (Novartis Institutes for BioMedical Research)

This website uses cookies.  More information.